梅萨拉诱导的炎症性肠病患者的急性胰腺炎:系统性审查
1Department of Pharmacy, Liuyang Hospital of Traditional Chinese Medicine, Changsha, Hunan, 410300, People's Republic of China.
Therapeutics and clinical risk management
|February 3, 2025
概括
在炎症性肠病 (IBD) 患者中,梅萨拉可以引起急性胰腺炎 (AP),通常在两周内. 停止药物通常会消除症状,但如果重新引入梅萨拉,反应可能会复发.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 梅萨拉是炎症性肠病 (IBD) 的首要治疗方法.
- 急性胰腺炎 (AP) 是一种罕见但已知的梅萨拉不良反应,首次报告于1989年.
- 之前的证据将梅萨拉辛与AP联系起来是基于病例报告和有限的回顾性研究.
研究的目的:
- 在患有炎症性肠病 (IBD) 的患者中研究由梅萨拉诱导的急性胰腺炎 (AP) 的特征.
- 分析临床表现,诊断发现和梅萨拉诱导的AP的结果.
- 评估 mesalazine 重复使用后AP的复发风险.
主要方法:
- 在多个数据库 (CNKI,万芳数据,VIP,PubMed,科学网) 进行了系统的文献搜索,截至2024年3月.
- 在IBD患者中收集了与美沙相关的AP病例报告.
- 对收集的病例报告进行了描述性分析.
主要成果:
- 该研究分析了34份报告,涉及42名患者的梅萨拉诱导的AP.
- 胰腺炎发作发生在梅萨拉开始后的中位数为14天,腹痛是最常见的症状 (100%).
- 血清粉酶/脂酶和成像检测结果的升高证实了胰腺炎;停止治疗导致所有病例的解决,在一周内改善了93.3%. 在21个案例中,重新挑战导致了复发.
结论:
- 梅萨拉诱导的AP是一种罕见但显著的不良药物反应.
- AP的发作并不依赖于剂量,并且可以在治疗期间随时发生,通常在两周内.
- 停止梅萨拉是有效的解决方案,但这种情况可能会在重新挑战时复发.
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
118
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
118
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
141
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
141
01:30Acute Pancreatitis II: Clinical Manifestations and Management
84
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
84
01:24Chronic Pancreatitis I: Introduction
64
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
64
01:29Chronic Pancreatitis II: Collaborative Care
60
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
60
01:29Inflammatory Bowel Disease IV: Pharmacological Management
100
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
100